PURPOSE: KRAS p.G12C mutations occur in approximately 3% of metastatic colorectal cancers (mCRC). Recently, two allosteric inhibitors of KRAS p.G12C have demonstrated activity in early phase clinical trials. There are no robust studies examining the behavior of this newly targetable population. METHODS: We queried the MD Anderson Cancer Center data set for patients with colorectal cancer who harbored KRAS p.G12C mutations between January 2003 and September 2019. Patients were analyzed for clinical characteristics, overall survival (OS), and progression-free survival (PFS) and compared against KRAS nonG12C. Next, we analyzed several internal and external data sets to assess immune signatures, gene expression profiles, hypermethylation, co-occurring mutations, and proteomics. RESULTS: Among the 4,632 patients with comprehensive molecular profiling, 134 (2.9%) were found to have KRAS p.G12C mutations. An additional 53 patients with single gene sequencing were included in clinical data but excluded from prevalence analysis allowing for 187 total patients. Sixty-five patients had de novo metastatic disease and received a median of two lines of chemotherapy without surgical intervention. For the first three lines of chemotherapy, the median PFS was 6.4 months (n = 65; 95% CI, 5.0 to 7.4 months), 3.9 months (n = 47; 95% CI, 2.9 to 5.9 months), and 3.0 months (n = 21; 95% CI, 2.0 to 3.4 months), respectively. KRAS p.G12C demonstrated higher rates of basal EGFR activation compared with KRAS nonG12C. When compared with an internal cohort of KRAS nonG12C, KRAS p.G12C patients had worse OS. CONCLUSION: PFS is poor for patients with KRAS p.G12C metastatic colorectal cancer. OS was worse in KRAS p.G12C compared with KRAS nonG12C patients. Our data highlight the innate resistance to chemotherapy for KRAS p.G12C patients and serve as a historical comparator for future clinical trials.
PURPOSE: KRAS p.G12C mutations occur in approximately 3% of metastatic colorectal cancers (mCRC). Recently, two allosteric inhibitors of KRAS p.G12C have demonstrated activity in early phase clinical trials. There are no robust studies examining the behavior of this newly targetable population. METHODS: We queried the MD Anderson Cancer Center data set for patients with colorectal cancer who harbored KRAS p.G12C mutations between January 2003 and September 2019. Patients were analyzed for clinical characteristics, overall survival (OS), and progression-free survival (PFS) and compared against KRAS nonG12C. Next, we analyzed several internal and external data sets to assess immune signatures, gene expression profiles, hypermethylation, co-occurring mutations, and proteomics. RESULTS: Among the 4,632 patients with comprehensive molecular profiling, 134 (2.9%) were found to have KRAS p.G12C mutations. An additional 53 patients with single gene sequencing were included in clinical data but excluded from prevalence analysis allowing for 187 total patients. Sixty-five patients had de novo metastatic disease and received a median of two lines of chemotherapy without surgical intervention. For the first three lines of chemotherapy, the median PFS was 6.4 months (n = 65; 95% CI, 5.0 to 7.4 months), 3.9 months (n = 47; 95% CI, 2.9 to 5.9 months), and 3.0 months (n = 21; 95% CI, 2.0 to 3.4 months), respectively. KRAS p.G12C demonstrated higher rates of basal EGFR activation compared with KRAS nonG12C. When compared with an internal cohort of KRAS nonG12C, KRAS p.G12C patients had worse OS. CONCLUSION: PFS is poor for patients with KRAS p.G12C metastatic colorectal cancer. OS was worse in KRAS p.G12C compared with KRAS nonG12C patients. Our data highlight the innate resistance to chemotherapy for KRAS p.G12C patients and serve as a historical comparator for future clinical trials.
Authors: Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester Journal: CA Cancer J Clin Date: 2017-01-17 Impact factor: 508.702
Authors: Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier Journal: N Engl J Med Date: 2009-04-02 Impact factor: 91.245
Authors: G R Blumenschein; E F Smit; D Planchard; D-W Kim; J Cadranel; T De Pas; F Dunphy; K Udud; M-J Ahn; N H Hanna; J-H Kim; J Mazieres; S-W Kim; P Baas; E Rappold; S Redhu; A Puski; F S Wu; P A Jänne Journal: Ann Oncol Date: 2015-02-26 Impact factor: 32.976
Authors: Jill Hallin; Lars D Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R Baer; Joshua A Ballard; Michael R Burkard; Jay B Fell; John P Fischer; Guy P Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F Patricoin; Douglas P Cassidy; Matthew A Marx; Igor I Rybkin; Melissa L Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P Papadopoulos; Pasi A Jänne; Peter Olson; James G Christensen Journal: Cancer Discov Date: 2019-10-28 Impact factor: 38.272
Authors: A Rose Brannon; Efsevia Vakiani; Brooke E Sylvester; Sasinya N Scott; Gregory McDermott; Ronak H Shah; Krishan Kania; Agnes Viale; Dayna M Oschwald; Vladimir Vacic; Anne-Katrin Emde; Andrea Cercek; Rona Yaeger; Nancy E Kemeny; Leonard B Saltz; Jinru Shia; Michael I D'Angelica; Martin R Weiser; David B Solit; Michael F Berger Journal: Genome Biol Date: 2014-08-28 Impact factor: 13.583
Authors: Mohamed E Salem; Sherif M El-Refai; Wei Sha; Alberto Puccini; Axel Grothey; Thomas J George; Jimmy J Hwang; Bert O'Neil; Alexander S Barrett; Kunal C Kadakia; Laura W Musselwhite; Derek Raghavan; Eric Van Cutsem; Josep Tabernero; Jeanne Tie Journal: JCO Precis Oncol Date: 2022-03